Evaluation of 1,5-anhydroglucitol, hemoglobin A1c, and glucose levels in youth and young adults with type 1 diabetes and healthy controls

Pediatric Diabetes

Volumn 13, Issue 3, 2012, Pages 278-284

  Mehta, Sanjeev N ^a   Schwartz, Natalie ^a   Wood, Jamie R ^b   Svoren, Britta M ^c   Laffel, Lori M B ^a  

^a JOSLIN DIABETES CENTER   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

1,5 anhydroglucitol; Diabetes mellitus; Glycosylated; Hemoglobin A; Pediatrics; Type 1

Indexed keywords

1,5 ANHYDROSORBITOL; CREATININE; GLUCOSE; HEMOGLOBIN A1C; INSULIN;

ADOLESCENT; ADULT; ARTICLE; BODY WEIGHT; CHILD; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHOOL CHILD; SEX DIFFERENCE;

ADOLESCENT; ADULT; BLOOD GLUCOSE; CHILD; COHORT STUDIES; DEOXYGLUCOSE; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE;

EID: 84860347799     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/j.1399-5448.2011.00830.x     Document Type: Article

References (25)

1. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993: 329: 977-986.
2. Kilpatrick ES, Rigby AS, Atkin SL. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2006: 29: 1486-1490.
3. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial-revisited. Diabetes 2008: 57: 995-1001.
4. Siegelaar SE, Holleman F, Hoekstra JB, DeVries JH. Glucose variability; does it matter? Endocr Rev 2010: 31: 171-182.
5. Goldstein DE, Little RR, Lorenz RA et al. Tests of glycemia in diabetes. Diabetes Care 2004: 27 (Suppl. 1): S91-S93.
6. Boland E, Monsod T, Delucia M, Brandt CA, Fernando S, Tamborlane WV. Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. Diabetes Care 2001: 24: 1858-1862.
7. Hirsch IB. Clinical review: Realistic expectations and practical use of continuous glucose monitoring for the endocrinologist. J Clin Endocrinol Metab 2009: 94: 2232-2238.
8. Pitkanen E. 1, 5-Anhydro-D-glucitol-a novel type of sugar in the human organism. Scand J Clin Lab Invest Suppl 1990: 201: 55-62.
9. Buse JB, Freeman JL, Edelman SV, Jovanovic L, McGill JB. Serum 1, 5-anhydroglucitol (GlycoMark): a short-term glycemic marker. Diabetes Technol Ther 2003: 5: 355-363.
10. Tetsuo M, Hamada T, Yoshimatsu K, Ishimatsu J, Matsunaga T. Serum levels of 1, 5-anhydro-D-glucitol during the normal and diabetic pregnancy and puerperium. Acta Obstet Gynecol Scand 1990: 69: 479-485.
11. Emoto M, Tabata T, Inoue T, Nishizawa Y, Morii H. Plasma 1, 5-anhydroglucitol concentration in patients with end-stage renal disease with and without diabetes mellitus. Nephron 1992: 61: 181-186.
12. Nerby CL, Stickle DF. 1, 5-anhydroglucitol monitoring in diabetes: a mass balance perspective. Clin Biochem 2009: 42: 158-167.
13. Yamanouchi T, Akanuma H, Nakamura T, Akaoka I, Akanuma Y. Reduction of plasma 1, 5-anhydroglucitol (1-deoxyglucose) concentration in diabetic patients. Diabetologia 1988: 31: 41-45.
14. Nowatzke W, Sarno MJ, Birch NC, Stickle DF, Eden T, Cole TG. Evaluation of an assay for serum 1, 5-anhydroglucitol (GlycoMark) and determination of reference intervals on the Hitachi 917 analyzer. Clin Chim Acta 2004: 350: 201-209.
15. Dungan KM. 1, 5-anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions. Expert Rev Mol Diagn 2008: 8: 9-19.
16. Nguyen TM, Rodriguez LM, Mason KJ, Heptulla RA. Serum 1, 5-anhydroglucitol (Glycomark) levels in children with and without type 1 diabetes mellitus. Pediatr Diabetes 2007: 8: 214-219.
17. Yamanouchi T, Akanuma H, Asano T et al. Reduction and recovery of plasma 1, 5-anhydro-D-glucitol level in diabetes mellitus. Diabetes 1987: 36: 709-715.
18. McGill JB, Cole TG, Nowatzke W et al. Circulating 1, 5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. trial of the GlycoMark assay. Diabetes Care 2004: 27: 1859-1865.
19. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation continuous glucose monitoring (JDRF-CGM) trial. Diabetes Care 2010: 33: 17-22.
20. Moses AC, Raskin P, Khutoryansky N. Does serum 1, 5-anhydroglucitol establish a relationship between improvements in HbA1c and postprandial glucose excursions? Supportive evidence utilizing the differential effects between biphasic insulin aspart 30 and insulin glargine. Diabet Med 2008: 25: 200-205.
21. Robertson DA, Alberti KG, Dowse GK, Zimmet P, Tuomilehto J, Gareeboo H, for the Mauritius Noncommunicable Diseases Study. Is serum anhydroglucitol an alternative to the oral glucose tolerance test for diabetes screening? The Mauritius Noncommunicable Diseases Study Group. Diabet Med 1993: 10: 56-60.
22. Shah S, Kublaoui BM, Oden JD, White PC. Screening for Type 2 Diabetes in Obese Youth. Pediatrics 2009: 124: 573-579.
23. Butterfield WJ, Keen H, Whichelow MJ. Renal glucose threshold variations with age. Br Med J 1967: 4: 505-507.
24. Kilpatrick ES, Keevilt BG, Richmond KL, Newland P, Addison GM. Plasma 1, 5-anhydroglucitol concentrations are influenced by variations in the renal threshold for glucose. Diabet Med 1999: 16: 496-499.
25. Herman WH, Dungan KM, Wolffenbuttel BH et al. Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1, 5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab 2009: 94: 1689-1694.